ClinicalTrials.gg
CompletedNCT05066997Updated May 5, 2026

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)

A Phase 2/3 interventional study of Dexamethasone ophthalmic suspension (OCS-01) and Vehicle in Diabetic Macular Edema, sponsored by Oculis. Completed at 52 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Oculis · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
552
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 56 studies testing dexamethasone in Macular Edema — 3 open to participants now, 3 under way, 1 of them phase 3. Dexamethasone · Macular Edema.

Enrollment
6th of 55
552 · median 50
Started
2021
with 3 others
Phase 2/3
2 of 56
none open now
Registered
50th of 56
by date
Lead sponsor
2 of 56
Oculis

Among the 56 studies testing dexamethasone in Macular Edema, this one is the 6th largest by enrollment of the 55 interventional ones that give a count, is one of 4 that started in 2021, is one of 2 in phase 2/3, and was the 50th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

3 of the 56 studies testing dexamethasone in Macular Edema are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing dexamethasone in Macular Edema, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS- 01 as compared to Vehicle in participants with Diabetic Macular Edema (DME).

Read the detailed description

A Phase 2/3 Pivotal Double-masked, Randomized, Vehicle-controlled, 2 stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Participants with Diabetic Macular Edema

Stage 1: To select a dose and dosing regimen for OCS-01 in participants with DME and evaluate the efficacy and safety of OCS-01 as compared to Vehicle in participants with DME.

Stage 2: To evaluate the efficacy and safety of OCS-01 as compared to Vehicle at Week 52 in participants with DME.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • Topical ophthalmic suspension
  • Eye drop
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (selection) - Stage 1:

  1. Have a signed form before any study-specific procedures are performed.
  2. Have DME with presence of intraretinal and/or subretinal fluid in the study eye, with central subfield thickness (CST) of ≥310 µm by SD-OCT at screening (Visit 1) (as assessed by an independent reading center).
  3. Have a documented diagnosis of type 1 or type 2 diabetes mellitus at Visit 1 (Screening).

Inclusion Criteria (selection) - Stage 2:

  1. Have a signed informed consent form before any study-specific procedures are performed.
  2. Have DME with presence of intraretinal and/or subretinal fluid in the study eye, with central subfield thickness (CST) of ≥310 µm by SD-OCT at screening (Visit 1) (as assessed by an independent reading center).
  3. Have a documented diagnosis of type 1 or type 2 diabetes mellitus prior to Visit 1 (Screening).

Exclusion criteria (selection) - Stage 1 and Stage 2:

  1. Have macular edema considered to be because of a cause other than DME.
  2. Have a decrease in BCVA because of causes other than DME.
  3. Have a known history of significant macular ischemia which would prevent gain in visual acuity in the study eye.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
552 participants (actual)

Study arms

  • Experimental
    OCS-01

    dexamethasone ophthalmic suspension,1.5% \[15 mg/ mL\]

    Drug: Dexamethasone ophthalmic suspension (OCS-01)

  • Placebo comparator
    Vehicle Vehicle

    Placebo is a Vehicle ophthalmic suspension of OCS-01

    Drug: Vehicle

Interventions

  • Stage 1: Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase). Stage 2: Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).

    Also known as: Dexamethasone

  • DrugVehicle

    Stage 1: Participants will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase). Stage 2: Participant will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Mean Change in BCVA (Best Corrected Visual Acuity)

    Assessed using ETDRS (Early Treatment Diabetes Retinopathy Study) letters score: higher numbers on the ETDRS chart representing better visual acuity

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants with a 3-line or Greater Gain in BCVA

    BCVA will be assessed by ETDRS letters score: higher numbers on the ETDRS chart representing better visual acuity.

    Time frame: Baseline, Week 52

  2. Mean Change in BCVA

    BCVA will be assessed using ETDRS letters score: higher numbers on the ETDRS chart representing better visual acuity.

    Time frame: Baseline, Week 12 and Week 24

  3. Mean Change in Central Subfield Thickness (CST)

    CST will be measured by SD-OCT.

    Time frame: Baseline, Week 52

Other outcomes

  1. Number of Participants With Treatment Emergent Adverse events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant. TEAEs are those AEs that occur after administration of the study product and are therefore temporally associated with the use of the study product.

    Time frame: Up to Week 52

07

Study locations

52 sites
  • Arizona Retina and Vitreous Consultants
    Phoenix, Arizona 85016, United States
  • Phoenix Retina Associates
    Phoenix, Arizona 85050, United States
  • Retina Partners of Northwest Arkansas
    Springdale, Arkansas 72764, United States
  • Retina-Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • The Retina Partners
    Encino, California 91436, United States
  • Retinal Consultants Medical Group
    Modesto, California 95356, United States
  • California Eye Specialists Medical Group
    Pasadena, California 91107, United States
  • California Eye Specialists Medical Group
    Redlands, California 92373, United States
  • Retina Consultants of Southern California
    Redlands, California 92374, United States
  • California Retina Consultants
    Santa Maria, California 93454, United States
  • Retina Group Of New England
    Waterford, Connecticut 06385, United States
  • Rand Eye Institute
    Deerfield Beach, Florida 33064, United States
  • Florida Retina Institute
    Jacksonville, Florida 32216, United States
  • MedEye Associates
    Miami, Florida 33143, United States
  • Florida Retina Institute
    Orlando, Florida 32806, United States
  • Retina Care Specialists
    Palm Beach Gardens, Florida 33410, United States
  • East Florida Eye Institute
    Stuart, Florida 34994, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Retina Associates
    Elmhurst, Illinois 60126, United States
  • University Retina
    Lemont, Illinois 60439, United States
  • Midwest Eye Institute
    Carmel, Indiana 46290, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
  • Retina Consultants of Minnesota
    Saint Louis Park, Minnesota 55416, United States
  • The Retina Institute
    St Louis, Missouri 63128, United States
  • Retina-Vitreous Surgeons of Central New York
    Liverpool, New York 13088, United States
  • North Carolina Retina Associates
    Wake Forest, North Carolina 27587, United States
  • Velocity (Meridian) Clinical Research
    Cincinnati, Ohio 45202, United States
  • Verum Research LLC
    Eugene, Oregon 97401, United States
  • Vision Research Solutions in Philadelphia
    Philadelphia, Pennsylvania 19141, United States
  • Retina Consultants of Charleston
    Beaufort, South Carolina 29902, United States
  • Charleston Neuroscience Institute
    Ladson, South Carolina 29456, United States
  • Black Hills Regional Eye Institute
    Rapid City, South Dakota 57701, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Retina Consultants of Austin/Austin Research Center for Retina
    Austin, Texas 78705, United States
  • Texas Retina Associates
    Dallas, Texas 75231, United States
  • Retina Center of Texas
    Grapevine, Texas 76051, United States
  • Valley Retina Institute PA d.b.a. Gulf Coast Eye Institute
    McAllen, Texas 78503, United States
  • Tyler Retina Consultants
    Tyler, Texas 75703, United States
  • Strategic Clinical Research Group
    Willow Park, Texas 76087, United States
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
  • HKU Eye Centre
    Hong Kong, Hong Kong
  • Chinese University of Hong Kong Eye Centre
    Kowloon, Hong Kong
  • Shivam Retina Clinic and Eye Hospital
    Surat, Gujarat 395001, India
  • Nethra Eye Hospital
    Bengaluru, Karnataka 560094, India
  • Amrita Institute of Medical Sciences & Research Centre
    Kochi, Kerala 682041, India
  • Sarakshi Netralaya
    Nagpur, Maharashtra 440025, India
  • L V Prasad Eye Institute
    Bhubaneswar, Odisha 751024, India
  • ICARE Eye Hospital & Post Graduate Institute
    Noida, Uttar Pradesh 201301, India
  • Changhua Christian Hospital
    Changhua, Changhua 500, Taiwan
  • China Medical University Hospital
    Taichung, Taichung 40447, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taipei 11217, Taiwan
  • Chang Gung Memorial Hospital
    Taoyuan, Taoyuan 33305, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Apr 2026, 53 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2021
First posted
Oct 4, 2021
StartActual
Oct 19, 2021
Primary completionActual
Apr 10, 2026
CompletionActual
Apr 10, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05066997
Lead sponsor
Oculis
Responsible party
Sponsor
First posted
Oct 4, 2021
Start date
Oct 19, 2021
Primary completion
Apr 10, 2026
Completion
Apr 10, 2026
Last update
May 5, 2026

Study contacts

Veeral S Sheth, MD
principal investigator · University Retina - Lemont

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion